Top 5 CRISPR Stocks To Buy

4. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 28

CRISPR Therapeutics AG (NASDAQ:CRSP) is a company that specializes in gene editing and aims to create gene-based medications for severe diseases using its CRISPR/Cas9 platform. This technology allows for highly specific and directed changes to the genomic DNA. CRISPR Therapeutics AG (NASDAQ:CRSP) has several therapeutic programs in its portfolio that address various disease areas, such as hemoglobinopathies, oncology, regenerative medicine, and rare diseases. It is one of the best CRISPR stocks to invest in. 

On April 13, Cantor Fitzgerald started coverage of CRISPR Therapeutics AG (NASDAQ:CRSP) with an Overweight rating and a price target of $72. According to the firm’s research note, CRISPR Therapeutics AG (NASDAQ:CRSP) is a promising gene editing company and an attractive investment option for 2023. The firm believes that the company has a strong likelihood of commercializing the first-ever CRISPR gene therapy later this year. Cantor Fitzgerald also sees the stock’s risk/reward potential as favorable, particularly for what they expect to be a busy and transformative year for CRISPR Therapeutics AG (NASDAQ:CRSP).

According to Insider Monkey’s fourth quarter database, 28 hedge funds were bullish on CRISPR Therapeutics AG (NASDAQ:CRSP), compared to 29 funds in the last quarter. Steven Boyd’s Armistice Capital is a significant position holder in the company, with 1 million shares worth $42 million. 

Follow Crispr Therapeutics Ag (NASDAQ:CRSP)